{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:58:13Z","timestamp":1794329893839,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004881","name":"Instituto Mexicano del Seguro Social","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009051","name":"Secretar\u00eda de Salud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C569\/A10404"],"award-info":[{"award-number":["C569\/A10404"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015381","name":"Instituto Nacional de Salud Publica","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015381","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vigilant management of women with high-risk human papillomavirus (hrHPV) is necessary in cancer screening programs. To this end, we evaluated the performance of S5 (targeting DNA methylation in HPV16, HPV18, HPV31, HPV33, and human gene <jats:italic>EPB41L3<\/jats:italic>) to predict cervical intraepithelial neoplasia grade 2 or higher (CIN2+) in a sample of hrHPV-infected women referred to colposcopy in the FRIDA Study, a large screening trial in Mexico. A nested case-control sample with women referred to colposcopy either by atypical squamous cells of undetermined significance or higher (ASCUS+) in cytology and\/or positive for HPV types 16 or 18 was tested by S5. Seventy-nine cases of CIN2+ were age-matched to 237 controls without a diagnosis of CIN2+ (&lt;CIN2). DNA from exfoliated cervical cells was bisulfite converted and PCR amplified for S5 targets, and methylation was quantified at specific cytosines by pyrosequencing.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The S5 classifier separated women with CIN2+ from &lt;CIN2 with a highly significant area under the curve (AUC) of 0.75 (95% CI 0.69\u20130.82), while AUC for CIN3+ was 0.81 (95% CI 0.74\u20130.89). To optimize sensitivity and specificity for Mexico, an alternative S5 cutoff of 3.7 was implemented to account for overall higher methylation seen in our already triaged women. All three invasive cancers were detected by methylation or HPV16\/18 but none by cytology. Sensitivity of S5 for CIN2+ was 62% (95% CI 50.4\u201372.7%), specificity was 73% (95% CI 66.9\u201378.5%), and adjusted PPV was 15.1% (95% CI 12.0\u201318.3%). In contrast, the crude sensitivity of HPV16\/18 detection and cytology were 63.3% (95% CI 51.7\u201373.9%) and 57.0% (95% CI 45.3\u201368.1%) respectively; specificity was 29.1% (95% CI 23.4\u201335.3%) and 62.4% (95% CI 55.9\u201368.6%) respectively, while adjusted PPV was 6.4% (95% CI 4.9\u20138.1%) and 10.5% (95% CI 8.0\u201313.1%), respectively. Methylation testing could reduce colposcopy referrals by 30 to 50% with virtually no loss of sensitivity for CIN2+ and CIN3+.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>S5 testing on hrHPV-positive women significantly increased diagnostic information compared to triage by HPV16\/18 plus cytology and appears to have clinical utility as an additional test to substantially lessen burdens on colposcopy.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The FRIDA Study is registered in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, number NCT02510027.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13148-019-0743-9","type":"journal-article","created":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T07:38:14Z","timestamp":1570865894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16\/18 genotyping"],"prefix":"10.1186","volume":"11","author":[{"name":"FRIDA Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00ed","family":"Hern\u00e1ndez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-4355","authenticated-orcid":false,"given":"Attila T.","family":"Lorincz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Torres-Ibarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Scibior-Bentkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian","family":"Warman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Nedjai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indira","family":"Mendiola-Pastrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leith","family":"Le\u00f3n-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenice","family":"Rivera-Paredez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ram\u00edrez-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Lazcano-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Cuzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Salmer\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,12]]},"reference":[{"key":"743_CR1","unstructured":"IARC. GLOBOCAN2018 [Internet]. [cited 2018 Dec 22]. Available from: \n                    https:\/\/gco.iarc.fr\/today\/online-analysis-multi-bars?v=2018&mode=cancer&mode_population=countries&population=900&populations=484&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=6&ages_group%5B%5D=12&nb_items=10&"},{"key":"743_CR2","doi-asserted-by":"crossref","unstructured":"Popat K, McQueen K, Feeley TW. The global burden of cancer. Best practice & research Clinical anaesthesiology. 2013;27(4).","DOI":"10.1016\/j.bpa.2013.10.010"},{"issue":"9590","key":"743_CR3","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","volume":"370","author":"Mark Schiffman","year":"2007","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590).","journal-title":"The Lancet"},{"issue":"10","key":"743_CR4","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s10552-010-9598-2","volume":"21","author":"Eduardo Lazcano-Ponce","year":"2010","unstructured":"Lazcano-Ponce E, Lorincz AT, Salmeron J, Fernandez I, Cruz A, Hernandez P, et al. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control. 2010;21(10).","journal-title":"Cancer Causes & Control"},{"key":"743_CR5","doi-asserted-by":"crossref","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Jounal Pathology. 1999;189(1).","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F"},{"key":"743_CR6","first-page":"7","volume":"164","author":"EL Franco","year":"2001","unstructured":"Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Cmaj. 2001;164:7.","journal-title":"Cmaj."},{"issue":"6","key":"743_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"Nubia Mu\u00f1oz","year":"2003","unstructured":"Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal Medicine. 2003;348(6).","journal-title":"New England Journal of Medicine"},{"key":"743_CR8","first-page":"3","volume":"9","author":"AT Lorincz","year":"1992","unstructured":"Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster WKR. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;9:3.","journal-title":"Obstet Gynecol."},{"key":"743_CR9","first-page":"9","volume":"9","author":"S Ratnam","year":"2000","unstructured":"Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000;9:9.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"4","key":"743_CR10","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ijc.29438","volume":"137","author":"Nicole G. Campos","year":"2015","unstructured":"Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, et al. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. International journal of cancer. 2015;137(4).","journal-title":"International Journal of Cancer"},{"issue":"9916","key":"743_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"Guglielmo Ronco","year":"2014","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383(9916).","journal-title":"The Lancet"},{"issue":"2","key":"743_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/aje\/kwp390","volume":"171","author":"P. E. Castle","year":"2009","unstructured":"Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. American journal of epidemiology. 2010;171(2).","journal-title":"American Journal of Epidemiology"},{"issue":"8","key":"743_CR13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1086\/343816","volume":"186","author":"Mark Schiffman","year":"2002","unstructured":"Schiffman M, Wheeler CM, Castle PE. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. Journal of Infect Dissease. 2002;186(8).","journal-title":"The Journal of Infectious Diseases"},{"key":"743_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ypmed.2011.08.017","volume":"53","author":"JE Tota","year":"2011","unstructured":"Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011;53:1.","journal-title":"Prev Med."},{"issue":"Suppl. 3","key":"743_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.vaccine.2006.05.117","volume":"24","author":"M Arbyn","year":"2006","unstructured":"Arbyn M, Sasieni P, Meijer CJLM, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl. 3):78\u201389.","journal-title":"Vaccine."},{"issue":"1","key":"743_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jcv.2013.06.041","volume":"58","author":"Arundhati Rao","year":"2013","unstructured":"Rao A, Sandri MT, Sideri M, Young S, Sharma A, Behrens C. Comparison of hybrid capture 2 high-risk HPV results in the low positive range with cobas\u00ae HPV test results from the ATHENA study. Journal of Clinical Virology. 2013;58(1).","journal-title":"Journal of Clinical Virology"},{"key":"743_CR17","doi-asserted-by":"crossref","unstructured":"Fields RP. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. New England Journal Medicine. 2008;358(6).","DOI":"10.1056\/NEJMc073199"},{"issue":"2","key":"743_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10552-010-9694-3","volume":"22","author":"Yvonne N. Flores","year":"2010","unstructured":"Flores YN, Bishai DM, Lorincz A, Shah KV, Lazcano-Ponce E, Hernandez M, et al. HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico. Cancer Causes Control. 2011;22(2).","journal-title":"Cancer Causes & Control"},{"issue":"16","key":"743_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa071430","volume":"357","author":"Marie-H\u00e9l\u00e8ne Mayrand","year":"2007","unstructured":"Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. New England Journal Medicine. 2007;357(16).","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"743_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40258-014-0135-4","volume":"13","author":"Warner K. Huh","year":"2014","unstructured":"Huh WK, Williams E, Huang J, Bramley T, Poulios N. Cost effectiveness of human papillomavirus-16\/18 genotyping in cervical cancer screening. Applied Health Economics and Health Policy. 2015;13(1).","journal-title":"Applied Health Economics and Health Policy"},{"issue":"1","key":"743_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ijc.23519","volume":"123","author":"Hung-Cheng Lai","year":"2008","unstructured":"Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, et al. Identification of novel DNA methylation markers in cervical cancer. International Journal of Cancer. 2008;123(1):161\u2013167.","journal-title":"International Journal of Cancer"},{"issue":"3","key":"743_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ijc.28050","volume":"133","author":"Attila T Lorincz","year":"2013","unstructured":"Lorincz AT, Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Castanon A, Fiander A, et al. HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. International Journal of Cancer. 2013;133(3).","journal-title":"International Journal of Cancer"},{"issue":"6","key":"743_CR23","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/ijc.27750","volume":"132","author":"Lisa Mirabello","year":"2012","unstructured":"Mirabello L, Schiffman M, Ghosh A, Rodriguez AC, Vasiljevic N, Wentzensen N, et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. International Journal of Cancer. 2013;132(6).","journal-title":"International Journal of Cancer"},{"issue":"3","key":"743_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1586\/14737159.2014.897610","volume":"14","author":"Attila T Lorincz","year":"2014","unstructured":"Lorincz AT. Cancer diagnostic classifiers based on quantitative DNA methylation. Expert review of molecular diagnostics. 2014;14(3).","journal-title":"Expert Review of Molecular Diagnostics"},{"issue":"7","key":"743_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/embor.2011.110","volume":"12","author":"H\u00e9l\u00e8ne Denis","year":"2011","unstructured":"Denis H, Ndlovu MN, Fuks F. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep. 2011;12(7).","journal-title":"EMBO reports"},{"key":"743_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijc.29196","volume":"136","author":"K Louvanto","year":"2015","unstructured":"Louvanto K, Franco EL, Ramanakumar AV, Vasiljevi N, Scibior-Bentkowska D, Koushik A, et al. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. International Journal of Cancer. 2015;136:6.","journal-title":"International Journal of Cancer."},{"issue":"3","key":"743_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jcv.2013.12.014","volume":"59","author":"Nata\u0161a Vasiljevi\u0107","year":"2014","unstructured":"Vasiljevi\u0107 N, Scibior-Bentkowska D, Brentnall A, Cuzick J, Lorincz A. A comparison of methylation levels in HPV18, HPV31 and HPV33 genomes reveals similar associations with cervical precancers. Journal of Clinical Virology. 2014;59(3).","journal-title":"Journal of Clinical Virology"},{"key":"743_CR28","doi-asserted-by":"crossref","unstructured":"Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, et al. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. International Journal of Cancer. 2018.","DOI":"10.1002\/ijc.31976"},{"issue":"7","key":"743_CR29","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/ijc.31549","volume":"143","author":"Belinda Nedjai","year":"2018","unstructured":"Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, et al. Molecular progression to cervical precancer, epigenetic switch or sequential model? International Journal of Cancer. 2018;143(7).","journal-title":"International Journal of Cancer"},{"issue":"6","key":"743_CR30","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/ijc.28790","volume":"135","author":"Adam R. Brentnall","year":"2014","unstructured":"Brentnall AR, Vasiljevic\u0308 N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, et al. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. International Journal of Cancer. 2014;135(6).","journal-title":"International Journal of Cancer"},{"issue":"5","key":"743_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3233\/CBM-150507","volume":"15","author":"Adam R. Brentnall","year":"2015","unstructured":"Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, et al. HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and EPB41L3 methylation classifier. Cancer Biomarkers. 2015;15(5).","journal-title":"Cancer Biomarkers"},{"issue":"11","key":"743_CR32","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/ijc.30008","volume":"138","author":"Attila T. Lorincz","year":"2016","unstructured":"Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. International Journal of Cancer. 2016;138(11).","journal-title":"International Journal of Cancer"},{"key":"743_CR33","doi-asserted-by":"crossref","unstructured":"Van BR, Van Der MJ, Snijders PJF, Rodriquez-manfredi A, Harmsel B, Van Den MHAM, et al. CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies. International Journal of Cancer. 2016;138.","DOI":"10.1002\/ijc.29706"},{"issue":"11","key":"743_CR34","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.biochi.2012.07.014","volume":"94","author":"Alexandre How Kit","year":"2012","unstructured":"How Kit A, Nielsen HM, Tost J. DNA methylation based biomarkers: practical considerations and applications. Biochimie. 2012;94(11).","journal-title":"Biochimie"},{"key":"743_CR35","doi-asserted-by":"crossref","unstructured":"Clarke MA, Luhn P, Gage JC, Bodelon C, Dunn ST, Walker J, et al. Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. International Journal of Cancer. 2017;710.","DOI":"10.1002\/ijc.30781"},{"issue":"9","key":"743_CR36","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","volume":"24","author":"Megan A. Clarke","year":"2018","unstructured":"Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, et al. Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women. Clinical Cancer Research. 2018;24(9).","journal-title":"Clinical Cancer Research"},{"key":"743_CR37","doi-asserted-by":"crossref","unstructured":"Schmitz M, Eichelkraut K, Schmidt D, Zeiser I, Hilal Z, Tettenborn Z, et al. Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages. BMC Cancer. 2018;18(1).","DOI":"10.1186\/s12885-018-5125-8"},{"key":"743_CR38","doi-asserted-by":"crossref","unstructured":"Floore A, Hesselink A, O\u0161trbenk A, Alcaniz E, Rothe B, Pedersen H, et al. Intra- and inter-laboratory agreement of the FAM19A4\/mir124-2 methylation test: results from an international study. 2019;33(e22854).","DOI":"10.1002\/jcla.22854"},{"key":"743_CR39","doi-asserted-by":"crossref","unstructured":"Schmitz M, Wunsch K, Hoyer H, Scheungraber C, Runnebaum IB, Hansel A, et al. Performance of a methylation specific real-time PCR assay as a triage test for HPV-positive women. Clinical epigenetics. 2017;9.","DOI":"10.1186\/s13148-017-0419-2"},{"issue":"3","key":"743_CR40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ygyno.2014.02.001","volume":"132","author":"Nata\u0161a Vasiljevi\u0107","year":"2014","unstructured":"Vasiljevi\u0107 N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecologic Oncology. 2014;132(3).","journal-title":"Gynecologic Oncology"},{"key":"743_CR41","doi-asserted-by":"crossref","unstructured":"Lorincz AT. Virtues and weaknesses of DNA methylation as a test for cervical cancer. Acta Cytologica. 2016.","DOI":"10.1159\/000450595"},{"key":"743_CR42","doi-asserted-by":"crossref","unstructured":"Lazcano-Ponce E, Lorincz A, Torres L, Salmer\u00f3n J, Cruz A, Rojas R. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. International Journal of Cancer. 2014;116.","DOI":"10.1002\/ijc.28639"},{"issue":"5","key":"743_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.21149\/spm.v56i5.7374","volume":"56","author":"Christyn M Beal","year":"2014","unstructured":"Beal CM, Salmer\u00f3n J, Flores YN, Torres L, Granados-garc\u00eda V, Dugan E, et al. Cost analysis of different cervical cancer screening strategies in Mexico. Salud Publica de Mexico. 2014;56(5).","journal-title":"Salud P\u00fablica de M\u00e9xico"},{"key":"743_CR44","unstructured":"de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The lancet oncology [Internet]. 2010 Nov [cited 2014 Jul 23];11(11). Available from: \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20952254"},{"issue":"22","key":"743_CR45","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/jnci\/djs425","volume":"104","author":"Nicolas Wentzensen","year":"2012","unstructured":"Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst. 2012;104(22).","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"743_CR46","doi-asserted-by":"crossref","unstructured":"Snijders P, Cubie H, Lorincz A, Ogilvie G, Franceschi S, Arbyn M, et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs. International Journal of Cancer. 2018;143(4).","DOI":"10.1002\/ijc.31261"},{"issue":"2","key":"743_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.21149\/spm.v58i2.7789","volume":"58","author":"Leticia Torres-Ibarra","year":"2016","unstructured":"Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hern\u00e1ndez-\u00c1vila M, Lorincz A, et al. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA study. Salud Publica de Mexico. 2016;58(2).","journal-title":"Salud P\u00fablica de M\u00e9xico"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-019-0743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-019-0743-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-019-0743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T23:04:58Z","timestamp":1602371098000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-019-0743-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1186\/s13148-019-0743-9","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,12]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The FRIDA study was reviewed and approved by the research and ethics committees of the Instituto Nacional de Salud P\u00fablica (INSP) (1094), Mexican regulatory agency COFEPRIS (CAS\/OR\/01\/CAS\/123300410C0044-3578\/2012), and Tlaxcala State Ministry of Health (SSET) (SS.DECI-OI-13\/12). The purpose and procedures of the study were explained to all participants, and informed verbal consent was obtained. The FRIDA Study design and management were supported by a group of principal investigators, steering committee, and subcommittees including molecular triage, quality control of cytology and pathology, and safety and case management.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JS and ELP have received funding for research projects from Qiagen, Roche, Beckton Dickinson, Gen-Probe, DICIPA, and Arbor Vita. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}